NACDS celebrates successful 2018 TSE by announcing 2019 plans
After closing out 2018 Total Store Expo in Denver at the end of August, the National Association of Chain Drug Stores is celebrating the success of the meeting, while gearing up for 2019.
Numerous educational sessions, influential speakers and unlimited networking opportunities were just a few of this year’s TSE’s highlights. Among the strategic business meetings that took place, and one of TSE’s biggest attractions was “Meet the Market,” a special program designed to introduce the latest innovative products, technology and services to the retail audience. Participating exhibitors presented their company and products to retailers through a series of 10-minute appointments.
Attendees also discovered the latest products and services from innovative suppliers of consumer goods, pharmacy, supply chain and logistics technology during a full one-day floor exhibition.
NACDS is already going full steam ahead with its plans for 2019 TSE, slated to be held in Boston from Aug. 24 to 26, 2019.
AAP, FDS partner to boost pharmacy members’ profitability
The American Associated Pharmacies and FDS, a pharmacy-centric healthcare technology company, are partnering to bring AAP members ProfitAmp, a groundbreaking business analytics tool to improve their pharmacies’ performance and profitability.
ProfitAmp provides powerful business intelligence and a unique level of detail that cannot be obtained with other BI tools on the market, according to the company.
“FDS is committed to helping pharmacies improve efficiency while positively impacting their bottom line, a mission that aligns well with AAP’s goal of providing member pharmacies with tools to enhance profitability, streamline operations and improve care quality,” AAP’s vice president of preferred partners Tracie Heyrman said. “Partnering with FDS to bring our members impactful BI solutions from an industry-leading technology company was a natural pairing, one we expect will deliver significant value and rapid ROI, while improving patient outcomes and strengthening the pharmacy-patient relationship.”
Available exclusively to AAP members, ProfitAmp delivers a deeper look into pharmacy operations, including an analysis of dispensing data through the Pharmacy Management System to identify key dispensing trends, lost patients and income opportunities. It also enables AAP to design organizational strategies around the health of its community to improve member pharmacies’ revenues and profits based on aggregate membership performance.
“The goal of this partnership is to continue providing AAP members with the solutions they needed to excel in today’s pharmacy marketplace. Our business intelligence and analytics tools leverage data from their existing pharmacy systems to drive financial, clinical and operational growth, and improve patient outcomes,” FDS executive vice president of business development Rich Bukovinsky said. “We take pride in the continued confidence and trust that AAP has placed in FDS’ products and services, and look forward to delivering true value to its member pharmacies.”
FDA approves Teva’s Cassipa for treatment of opioid dependence
The Food and Drug Administration has given the nod to Teva’s Cassipa (buprenorphine and naloxone) sublingual film, or applied under the tongue, for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 ml/4 ml) of buprenorphine and naloxone sublingual film, which also is approved in both brand name and generic versions, as well as in various strengths.
“There’s an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder. The introduction of new treatment options has the potential to broaden access for patients. For example, the FDA recently described a streamlined approach to drug development for certain medication-assisted treatments that are based on buprenorphine. This streamlined approach can reduce drug development costs, so products may be offered at a lower price to patients, and we can broaden access to treatment,” FDA commissioner Scott Gottlieb said.
Gottlieb also said that the FDA is committed to helping those with opioid use disorder transition to lives of sobriety.
“We’ve taken a number of steps to advance the development of new FDA-approved treatments for opioid dependence and encourage healthcare professionals to ensure patients are offered an adequate chance to benefit from these therapies. We’re also working to address the unfortunate stigma that’s sometimes associated with the use of opioid replacement therapy as one approach to the successful treatment of addiction. Despite what some may think, individuals who successfully transition onto medication-assisted treatment are not swapping one addiction for another. Opioid replacement therapy can be an important part of effective treatment. Opioid use disorder should be viewed similarly to any other chronic condition that is treated with medication,” Gottlieb said in a statement.
In June, the FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film in multiple strengths.